Immunology June 21, 2023 Eli Lilly and Company agrees to acquire DICE Therapeutics By PBR Staff Writer Under the deal terms, Lilly will begin a tender offer to purchase all outstanding shares of DICE for an acquisition price of $48 per share in cash, which translates to a total
Regulation June 20, 2023 F2G receives Complete Response Letter for olorofim NDA By PBR Staff Writer The NDA was accepted by the regulatory agency for review with a PDUFA target action date set for 17 June 2023. As per the CRL, the regulatory body
Production & Sales June 19, 2023 Rosemont Pharmaceuticals acquires Lucis Pharma By PBR Staff Writer With the acquisition, Rosemont will expand its existing portfolio and gain access to the new pipeline of products, providing lifesaving pharmaceuticals across the UK and within overseas markets.
Drug Discovery June 16, 2023 Sandoz launches action plan to improve access to biosimilar medicines By PBR Staff Writer Dubbed Act4Biosimilars Action Plan, the new roadmap has been designed to boost the adoption of global biosimilar products by at least 30% points in more than 30 countries
Drug Discovery June 15, 2023 Fresenius Kabi introduces Vasopressin Injection, USP, in US By PBR Staff Writer Vasopressin Injection is a generic equivalent to Par Pharmaceutical’s Vasostrict and is available in a single dose vial of 20 units per 1 mL. Fresenius has invested nearly
RegulationApprovals June 14, 2023 Eupraxia’s EP-104IAR secures US FDA Fast Track status By PBR Staff Writer EP-104IAR has been designed for meeting the market demand for long-lasting disease relief in many indications and gain benefit from highly localised and longer delivery of corticosteroids. It
Drug DiscoveryResearch & Development June 13, 2023 Charles River Laboratories, Curigin partner on gene therapy By PBR Staff Writer The partnership will focus on the production of adenoviral vector. Under the collaboration, Curigin will use the capabilities of Charles River in contract development and manufacturing organisation (CDMO)
Drug DiscoveryResearch & Development June 12, 2023 EdgeCap Partners buys majority stake in Comac Medical By PBR Staff Writer Comac founder and CEO Dr Milen Vrabevski and its other shareholders will retain a significant minority stake. The companies have not disclosed the financial terms of the deal.
Women's Health June 9, 2023 Cosette acquires worldwide rights to Endoceutics’ Intraros prescription drug By PBR Staff Writer The transaction includes 108 issued and pending patents globally with the latest expiring this year including three Orange Book listed patents. The acquisition will expedite Cosette’s women’s health
Drug Manufacturing June 8, 2023 Samsung Biologics, Pfizer partner for biosimilars portfolio manufacturing By PBR Staff Writer Initially, the companies signed a manufacturing agreement in March last year for a Pfizer product. As per the new agreement terms, Samsung Biologics will provide Pfizer with more